Atlas Trials

Janssen-Cilag Ltd.

34 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Janssen-Cilag Ltd.

RecordFirmDate
A Study of Guselkumab Treatment Persistence in Psoriatic Arthritis Participants (NCT07532226)Janssen-Cilag Ltd.2026-04-17
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis (NCT07449234)Janssen-Cilag Ltd.2026-02-09
A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK) (NCT07242248)Janssen-Cilag Ltd.2025-11-17
A Real-world Study in Participants With Smoldering Multiple Myeloma (NCT06472778)Janssen-Cilag Ltd.2024-05-31
A Study of Participants With Moderate or Severe Major Depressive Disorder (MDD) Requiring Urgent Symptom Control in a Psychiatric Emergency (NCT04829669)Janssen-Cilag Ltd.2024-04-30
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (NCT06408935)Janssen-Cilag Ltd.2024-04-17
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials (NCT06285318)Janssen-Cilag Ltd.2023-12-18
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide (NCT05901649)Janssen-Cilag Ltd.2023-07-05
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (NCT05347095)Janssen-Cilag Ltd.2022-09-27
A Long-Term Extension Study for Participants With Treatment-resistant Major Depressive Disorder Who Are Continuing Esketamine Nasal Spray Treatment (NCT04829318)Janssen-Cilag Ltd.2021-04-26
A Study to Evaluate the Impact of Care4Today® IBD, a Smart System to Facilitate the Management of Crohn's Disease by Patients and Health Care Providers (NCT04232228)Janssen-Cilag Ltd.2020-02-07
A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (NCT03998683)Janssen-Cilag Ltd.2019-09-03
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment (NCT04035226)Janssen-Cilag Ltd.2019-08-02
A Registry Study of Participants With Multiple Myeloma in Latin America (NCT03955900)Janssen-Cilag Ltd.2019-05-29
A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease (NCT03782376)Janssen-Cilag Ltd.2018-12-20
Treatment-Resistant Depression Cohort in Europe (NCT03373253)Janssen-Cilag Ltd.2018-02-13
Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (NCT03495973)Janssen-Cilag Ltd.2017-10-25

Track Janssen-Cilag Ltd. automatically

Every clearance here is in the API, with alerts when new ones post.